A real-world study has shown that next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) can be effective in a real-world setting to guide precision neuro-oncology treatment.
Researchers from the University of Hong Kong and Queen Mary Hospital, Hong Kong, and from ACT Genomics in Taipei, Taiwan, Republic of China, set up CGP for 43 patients at a tertiary neuro-oncology center who had either exhausted conventional treatment or required CGP for clinical trials.